Document is current
Any future updates will be listed below
-
Authors
Rahmani, Farzaneh
Nguyen, Marina
Chen, Charles D.
McKay, Nicole
Dincer, Aylin
Joseph-Mathurin, Nelly
Chen, Gengsheng
Liu, Jingxia
Orlowski, Hilary L. P.
Morris, John C.
Benzinger, Tammie L. S.
-
Funding
Funding for this research was provided by:
National Institute on Aging (P50AG005681, P01AG026276, P01AG003991, T32AG05851804)
National Institute of Neurological Disorders and Stroke (1P30NS098577)
National Institute of Biomedical Imaging and Bioengineering (R01 EB009352)
Foundation for Barnes-Jewish Hospital
McDonnell Center for Systems Neuroscience
National Center for Advancing Translational Sciences (UL1TR000448)
- License Information
-
More Information
Article History
Received: 15 September 2021
Accepted: 31 January 2022
First Online: 11 February 2022
Declarations
:
: The institutional ethics review board of Washington University School of Medicine in Saint Louis approved the protocol of this study. All participants consented to participate in the study and provided their informed consent to participate in the study. The study was in compliance with HIPAA and was performed in accordance with the Declaration of Helsinki.
: Not applicable
: Dr. Benzinger has investigator-initiated research funding from the NIH, the Alzheimer’s Association, the Barnes-Jewish Hospital Foundation, and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). Dr. Benzinger participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Jansen, and Roche; is an unpaid consultant to Eisai and Siemens; and is on an Advisory Board and Speaker’s Bureau for Biogen.
